Welcome to Immunopharmacology of Cancer
Our overall aim is to develop novel treatments to enhance the body's immune defenses against cancer.
Our research aims first at uncovering new mechanisms leading to activation of the immune system, for example during viral infections. Using this bioinspiration, our goal is to develop pharmacological ways to stimulate anticancer immunity.
We are currently working on the following questions:
- What is the early sequence of immune activation during a viral infection? How can we reproduce this sequence pharmacologically?
- How do virally-derived components, such as Toll-like receptor ligands, activate anti-cancer immunity and decrease cancer-associated immunosuppression?
- Can we enhance migration of effector T cells into the tumor with virally-derived components?
- Can we use nanoparticles as delivery system to focus their action and prevent unwanted side effects?
You can find more detailed information on the ongoing projects in “link to Research section”
The Egon Naef Foundation for In Vitro Research awards its 3R Prize to Professor Carole Bourquin of the University of Geneva
Carole Bourquin receives the Egon Naef Foundation 3R Prize in recognition for the development of a new in vitro technique that reduces by 20% the number of mice needed for nanoparticle research in immunotherapy.
Interview of Prof. Carole Bourquin on RTS radio "Le rôle de l'inflammation dans le cancer"
Click to listen to this interview :
SSAI Travel Grant Winner of WIRM-XIII, April 5-9, 2019, Davos (Switzerland) (Travel grant of CHF 670.-)
BioLegend Workshop Award Winner of WIRM-XIII, April 5-9, 2019, Davos (Switzerland)